<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927793</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 938-009</org_study_id>
    <nct_id>NCT04927793</nct_id>
  </id_info>
  <brief_title>Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects</brief_title>
  <official_title>A Phase I, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]EDP-938 Following a Single Oral Dose in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Open-label Study of the absorption, metabolism, and excretion of a single oral&#xD;
      dose of [14C]EDP-938 in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of EDP-938 in plasma</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tlast of EDP-938 in plasma</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC-inf in plasma</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount excreted in urine (Aeu)</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount excreted in feces (Aef)</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of EDP-938 metabolites in plasma</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety measured by occurrence of adverse events</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Respiratory Syncytial Virus (RSV)</condition>
  <arm_group>
    <arm_group_label>Single arm EDP-938</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-938</intervention_name>
    <description>[14C]EDP-938</description>
    <arm_group_label>Single arm EDP-938</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males of any ethnic origin, between 18 and 55 years of age, inclusive.&#xD;
&#xD;
          -  Able to comprehend and willing to sign an Informed Consent Form&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination (check-in only), 12-lead ECG, vital signs measurements, and&#xD;
             clinical laboratory evaluations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the investigator (or designee).&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection, including cholecystectomy, that&#xD;
             would potentially alter absorption and/or excretion of orally administered drugs&#xD;
             (uncomplicated appendectomy and hernia repair will be allowed).&#xD;
&#xD;
             a. Subjects with a history of cholecystitis, cholelithiasis, and/or&#xD;
             choledocholithiasis will also be excluded.&#xD;
&#xD;
          -  Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to&#xD;
             screening, or platelets from 6 weeks prior to screening.&#xD;
&#xD;
          -  A body surface area-adjusted estimated glomerular filtration rate (eGFR) â‰¤ 90 mL/min&#xD;
             per 1.73 m2 according to the Chronic Kidney Disease Epidemiology Collaboration&#xD;
             (CKD-EPI) equation, at screening&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <phone>857 760 0548</phone>
    <email>gdelarosa@enanta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AME Study</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

